NewAmsterdam Pharma Company N.V.
Symbool: NAMS
NASDAQ
21.86
USDMarktprijs vandaag
87.5675
Koers/Winst Verhouding
0.0000
Koers/Winst Groei Verhouding
1.95B
MRK Kapitalisatie
- 0.00%
DIV Rendement
NewAmsterdam Pharma Company N.V. (NAMS) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 340.4 | 438.5 | 53.1 | ||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.net-receivables | 0 | 1.9 | 1.9 | 4.3 | ||||
balance-sheet.row.inventory | 0 | -1.9 | 0 | 0 | ||||
balance-sheet.row.other-current-assets | 0 | 6.3 | 7.6 | 1.5 | ||||
balance-sheet.row.total-current-assets | 0 | 346.8 | 448.1 | 58.9 | ||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.goodwill | 0 | 0 | 0.2 | 0 | ||||
balance-sheet.row.intangible-assets | 0 | 0.2 | 82.9 | 0 | ||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.2 | 83.2 | 0 | ||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0.1 | 0 | ||||
balance-sheet.row.total-non-current-assets | 0 | 0.3 | 83.5 | 0.9 | ||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-assets | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.account-payables | 0 | 16.9 | 11.1 | 6.2 | ||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.1 | 0.1 | ||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 2.8 | ||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0.1 | 0.1 | ||||
Deferred Revenue Non Current | 0 | 1 | 4.5 | 0 | ||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||
balance-sheet.row.other-current-liab | 0 | 24 | 11.3 | 0 | ||||
balance-sheet.row.total-non-current-liabilities | 0 | 8.8 | 11.6 | 0.1 | ||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.capital-lease-obligations | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.total-liab | 0 | 58.7 | 47.1 | 10 | ||||
balance-sheet.row.preferred-stock | 0 | 317 | 0 | 0 | ||||
balance-sheet.row.common-stock | 0 | 10.2 | 599.2 | 83.9 | ||||
balance-sheet.row.retained-earnings | 0 | -317 | -119.4 | -34.7 | ||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 4.4 | 4.7 | 0.6 | ||||
balance-sheet.row.other-total-stockholders-equity | 0 | 273.8 | 0 | 0 | ||||
balance-sheet.row.total-stockholders-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 347.1 | 531.6 | 59.8 | ||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||
balance-sheet.row.total-equity | 0 | 288.4 | 484.5 | 49.8 | ||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||
Total Investments | 0 | 0 | 0 | 0.7 | ||||
balance-sheet.row.total-debt | 0 | 0.1 | 0.1 | 0.2 | ||||
balance-sheet.row.net-debt | 0 | -340.4 | -438.4 | -52.9 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -176.9 | -78.1 | -28.6 | ||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0.1 | 0 | ||||
cash-flows.row.deferred-income-tax | 0 | 5.2 | 0 | -1.4 | ||||
cash-flows.row.stock-based-compensation | 0 | 24.6 | 3.9 | 1 | ||||
cash-flows.row.change-in-working-capital | 0 | 5.9 | 11.5 | 3.8 | ||||
cash-flows.row.account-receivables | 0 | 3.7 | -3.9 | -4.6 | ||||
cash-flows.row.inventory | 0 | -3.7 | 5.9 | -0.1 | ||||
cash-flows.row.account-payables | 0 | 5.1 | -2 | 8.6 | ||||
cash-flows.row.other-working-capital | 0 | 0.8 | 11.5 | 0 | ||||
cash-flows.row.other-non-cash-items | 0 | 0 | 70.6 | 0 | ||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0.7 | 0 | ||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | ||||
cash-flows.row.common-stock-issued | 0 | 8.1 | 377.8 | 69 | ||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||
cash-flows.row.other-financing-activites | 0 | 0.8 | -2.5 | 0 | ||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 8.9 | 375.2 | 69 | ||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5.1 | 1.6 | 1.4 | ||||
cash-flows.row.net-change-in-cash | 0 | -127.3 | 385.4 | 45.2 | ||||
cash-flows.row.cash-at-end-of-period | 0 | 340.4 | 438.5 | 53.1 | ||||
cash-flows.row.cash-at-beginning-of-period | 0 | 467.7 | 53.1 | 7.9 | ||||
cash-flows.row.operating-cash-flow | 0 | -141.2 | 8 | -25.2 | ||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||
cash-flows.row.free-cash-flow | 0 | -141.2 | 8 | -25.2 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | |||
---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 14.1 | 97.5 | 0 | ||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.gross-profit | 0 | 14 | 97.4 | 0 | ||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||
income-statement-row.row.research-development | 0 | - | - | - | ||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.other-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.operating-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.cost-and-expenses | 0 | 189.2 | 104.5 | 29.8 | ||||
income-statement-row.row.interest-income | 0 | 11.3 | 0 | 0 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||
income-statement-row.row.total-other-income-expensenet | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0.1 | 0 | ||||
income-statement-row.row.total-operating-expenses | 0 | -5.2 | -10.5 | 1.2 | ||||
income-statement-row.row.interest-expense | 0 | 0 | 0.3 | 0.2 | ||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 60.7 | 0 | ||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||
income-statement-row.row.operating-income | 0 | -183 | -67.6 | -29.8 | ||||
income-statement-row.row.income-before-tax | 0 | -176.9 | -78.1 | -28.6 | ||||
income-statement-row.row.income-tax-expense | 0 | 0 | 70.8 | 0.2 | ||||
income-statement-row.row.net-income | 0 | -176.9 | -148.9 | -28.8 |
Vaak gestelde vragen
Wat is NewAmsterdam Pharma Company N.V. (NAMS) totale activa?
NewAmsterdam Pharma Company N.V. (NAMS) totale activa is 347097000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 1.000.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.206.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.335.
Wat is NewAmsterdam Pharma Company N.V. (NAMS) nettowinst (netto-inkomen)?
De nettowinst is -176937000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 60000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 189195000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.